Retrospective investigation of the clinical effects of tazobactam/ piperacillin and sulbactam/ampicillin on aspiration pneumonia caused by Klebsiella pneumoniae

Journal of Infection and Chemotherapy

Volumn 18, Issue 5, 2012, Pages 715-721

  Tsukada, Hiroki ^a   Sakai, Kunihiko ^b   Cho, Hiromi ^a   Kimura, Yuka ^a   Tetsuka, Takafumi ^a   Nakajima, Haruhiko ^a   Ito, Kazuhiko ^a  

^a NIIGATA CITY GENERAL HOSPITAL   (Japan)

^b Niigata Rinko Hospital   (Japan)

Author keywords

Aspiration pneumonia; Klebsiella pneumoniae; Sulbactam ampicillin; Tazobactam piperacillin

Indexed keywords

AMPICILLIN; C REACTIVE PROTEIN; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; ASPIRATION PNEUMONIA; BACTERIUM DETECTION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG EFFICACY; ESCHERICHIA COLI; HUMAN; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MORTALITY; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE;

EID: 84871364324     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0407-6     Document Type: Article

References (17)

1. Teramoto S, Fukuchi Y, Sasaki H, Sato K, Sekizawa K, Matsuse T. High incidence of aspiration pneumonia in community-and hospital-acquired pneumonia in hospitalized patients: a multicenter, prospective study in Japan. J Am Geriatr Soc. 2008;56:577-9.
2. The JRS guidelines for the management of community-acquired pneumonia in adults. The committee for the JRS guidelines in management of respiratory infections. Tokyo, Japan; 2007.
3. Gilbert D, Moellering R, Eliopoulos G, Chambers H, Saag M. The Sanford guide to antimicrobial therapy 2011. 41st ed. USA: Antimicrobial Therapy Inc.; 2011. p. 40.
4. Shiraishi T, Sakamoto T, Iwatake M, Nakamura Y, Yokoyama H. A survey of antibiotic treatment for aspiration pneumonia. J Jpn Soc Hosp Pharm. 2009;45:1501-4.
5. Kaneko A, Yamane N, Watanabe D, Mizusawa N, Matsuzaki K, Hasegawa M, et al. Treatment of aspiration pneumonia based on the antimicrobial susceptibility pattern of oral bacterial pathogens. Jpn J Chemother. 2007;55:378-81.
6. Kubo H. Aspiration pneumonia in elderly. Antibiot Chemother. 2009;25:1853-8.
7. The JRS Guidelines for the management of hospital-acquired pneumonia in adults. The committee for the JRS guidelines in management of respiratory infections. Tokyo, Japan; 2008.
8. Report of the committee for the respiratory system, Japan Society of Chemotherapy. Clinical evaluation methods for new antimicrobial agents to treat respiratory infections (draft). Jpn J Chemother. 1997;45:762-78.
9. Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Hashimoto N, et al. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. Chest. 2009;135:633-40.
10. Hirakata Y, Matsuda J, Miyazaki Y, Kamihira S, Kawakami S, Miyazawa Y, et al. Regional variation in the prevalence of extended-spectrum b-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn Microbiol Infect Dis. 2005;52:323-9.
11. Muratani T. The actual situation in Japan of antimicrobial resistant isolates from patients with urinary tract infection and its method of prevention and control. Antibiot Chemother. 2009;25:413-23.
12. Bradford PA. Extended-spectrum b-lactamase in the 21th century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001;14:933-51.
13. Iinuma Y. Basics and clinics of resistant bacteria: problematic resistant bacteria mainly for hospital infection: Escherichia coli (clinical volume). J Med Technol. 2006;50:698-703.
14. The JRS Guidelines for the management of nursing and healthcare pneumonia. The committee for the JRS guidelines in management NHCAP. Tokyo, Japan; 2011.
15. Metlay JP, Schulz R, Li YH, Singer DE, Marrie TJ, Coley CM, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med. 1997;157:1453-9.
16. Niki Y, Hanaki T, Matsumoto T, Yagisawa H, Kohno S, Aoki N, et al. Nation wide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens' antibacterial susceptibility. J Infect Chemother. 2009;15:156-67.
17. Jones RN, Stilwell MG, Rhomberg PR, Sader HS. Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007). Diagn Microbiol Infect Dis. 2009;65:331-4.